Literature DB >> 23744276

Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer.

Zi-Ming Li1, Zheng-Ping Ding1, Qing-Quan Luo1, Chun-Xiao Wu2, Mei-Lin Liao1, Ying Zhen2, Zhi-Wei Chen1, Shun Lu3.   

Abstract

BACKGROUND: The non-small cell lung cancer (NSCLC) staging system (published in 2009 in the seventh edition of the cancer staging manuals of the Union for International Cancer Control and American Joint Commission on Cancer) did not include any changes to current N descriptors for NSCLC. However, the prognostic significance of the extent of lymph node (LN) involvement (including the LN zones involved [hilar/interlobar or peripheral], cancer-involved LN ratios [LNRs], and the number of involved LNs) remains unknown. The aim of this report is to evaluate the extent of LN involvement and other prognostic factors in predicting outcome after definitive surgery among Chinese patients with stage II-N1 NSCLC.
METHODS: We retrospectively reviewed the clinicopathologic characteristics of 206 patients with stage II (T1a-T2bN1M0) NSCLC who had undergone complete surgical resection at Shanghai Chest Hospital from June 1999 to June 2009. Overall survival (OS) and disease-free survival (DFS) were compared using Kaplan-Meier statistical analysis. Stratified and Cox regression analyses were used to evaluate the relationship between the LN involvement and survival.
RESULTS: Peripheral zone LN involvement, cancer-involved LNR, smaller tumor size, and squamous cell carcinoma were shown to be statistically significant indicators of higher OS and DFS by univariate analyses. Visceral pleural involvement was also shown to share a statistically significant relationship with DFS by univariate analyses. Multivariate analyses showed that tumor size and zone of LN involvement were significant predictors of OS.
CONCLUSIONS: Zone of N1 LN, LN ratios, and tumor size were found to provide independent prognostic information in patients with stage II NSCLC. This information may be used to stratify patients into groups by risk for recurrence.

Entities:  

Mesh:

Year:  2013        PMID: 23744276     DOI: 10.1378/chest.13-0073

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

1.  Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection.

Authors:  Chen-Ping Hsieh; Ming-Ju Hsieh; Ching-Feng Wu; Jui-Ying Fu; Yun-Hen Liu; Yi-Cheng Wu; Cheng-Ta Yang; Ching-Yang Wu
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis.

Authors:  Qian Li; Ping Zhan; Dongmei Yuan; Tangfeng Lv; Alexander Sasha Krupnick; Antonio Passaro; Alessandro Brunelli; Matthew P Smeltzer; Raymond U Osarogiagbon; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  Pathologic N1 disease in lung cancer: the segmental and subsegmental lymph nodes.

Authors:  Marc Riquet; Ciprian Pricopi; Giuseppe Mangiameli; Alex Arame; Alain Badia; Françoise Le Pimpec Barthes
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

4.  Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.

Authors:  Yoichi Ohtaki; Kimihiro Shimizu; Kyoichi Kaira; Toshiteru Nagashima; Kai Obayashi; Seshiru Nakazawa; Seiichi Kakegawa; Hitoshi Igai; Mitsuhiro Kamiyoshihara; Masahiko Nishiyama; Izumi Takeyoshi
Journal:  Surg Today       Date:  2016-01-19       Impact factor: 2.549

5.  Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy.

Authors:  Paolo Borghetti; Fernando Barbera; Marco Lorenzo Bonù; Francesca Trevisan; Stefano Ciccarelli; Paola Vitali; Marta Maddalo; Luca Triggiani; Nadia Pasinetti; Sara Pedretti; Bartolomea Bonetti; Gianluca Pariscenti; Andrea Tironi; Alberto Caprioli; Michela Buglione; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2016-05-26       Impact factor: 3.469

6.  Lymph Node Metastasis Location and Postoperative Adjuvant Chemotherapy in Patients With pN1 Stage IIB Non-small Cell Lung Cancer.

Authors:  Ryuichi Ito; Takuma Tsukioka; Nobuhiro Izumi; Hiroaki Komatsu; Hidetoshi Inoue; Takuya Kimura; Kazuya Kishimoto; Noritoshi Nishiyama
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

7.  Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Evaluation of Patients With Newly Diagnosed Non-Small Cell Lung Cancer.

Authors:  Junhao Wu; Hao Deng; Haoshu Zhong; Tao Wang; Zijuan Rao; Yingwei Wang; Yue Chen; Chunyin Zhang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

8.  Detection of occult tumor cells in regional lymph nodes is associated with poor survival in pN0 non-small cell lung cancer: a meta-analysis.

Authors:  Zhicheng He; Yang Xia; Shaowen Tang; Yijiang Chen; Liang Chen
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

9.  Prognostic significance of the pattern of pathological N1 lymph node metastases for non-small cell lung cancer.

Authors:  Sergej Griff; Samantha Taber; Torsten T Bauer; Joachim Pfannschmidt
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

10.  Predictive value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and lymphocyte-to-monocyte ratio (LMR) in patients with non-small cell lung cancer after radical lung cancer surgery.

Authors:  Baoqian Zhai; Jia Chen; Jiacheng Wu; Lei Yang; Xiaoli Guo; Jingjing Shao; Hong Xu; Aiguo Shen
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.